SB-202190 (SB202190, SB 202190, FHPI) 是一种高效选择的的细胞渗透性的p38 MAPK抑制剂，抑制p38α (IC50：50 nM) 和p38β (IC50：100 nM)。SB-202190可以通过激活cpp32-like caspases途径诱导细胞凋亡，典型凋亡特征如核固缩或核内染色体DNA碎片化。

参考文献

[1]. Nemoto S, et al. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. J Biol Chem. 1998 Jun 26;273(26):16415-20.

[2]. Yang S, et al. Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia. Biomed Res Int. 2013;2013:215798.

[3]. Shanware NP, et al. Non-specific in vivo inhibition of CK1 by the pyridinyl imidazole p38 inhibitors SB 203580 and SB 202190. BMB Rep. 2009 Mar 31;42(3):142-7.

[4]. Berkowitz P, et al. p38MAPK inhibition prevents disease in pemphigus vulgaris mice. Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12855-60.

[5]. Hirosawa M, et al. The p38 pathway inhibitor SB202190 activates MEK/MAPK to stimulate the growth of leukemia cells. Leuk Res. 2009 May;33(5):693-9.

冰袋运输。粉末直接保存于-25~-15℃，有效期2年。建议避光干燥保存，避免反复冻融。